2025
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study
Donnez J, Petraglia F, Taylor H, Becker C, Becker S, Herrera F, Bestel E, Hori S, Dolmans M. Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study. Fertility And Sterility 2025 PMID: 40543832, DOI: 10.1016/j.fertnstert.2025.06.016.Peer-Reviewed Original ResearchHormonal add-back therapyAdd-back therapyHeavy menstrual bleedingMenstrual blood lossSymptomatic uterine fibroidsCessation of therapyMenstrual bleedingBone mineral densityUterine fibroidsBlood lossWithdrawal studyMineral densityPlacebo-controlled phase 3 trialTreatment of symptomatic uterine fibroidsDecreased menstrual blood lossReducing menstrual blood lossRisk of bone lossReducing heavy menstrual bleedingExtension studySignificantly higher proportion of womenMonths of therapyFibroid-associated symptomsPhase 3 trialAlkaline haematin methodBenefits of treatment
2024
Uterine fibroid–related infertility: mechanisms and management
Donnez J, Taylor H, Marcellin L, Dolmans M. Uterine fibroid–related infertility: mechanisms and management. Fertility And Sterility 2024, 122: 31-39. PMID: 38453041, DOI: 10.1016/j.fertnstert.2024.02.049.Peer-Reviewed Original ResearchUterine artery embolizationUterine fibroidsAssociation of fibroidsAdd-back therapyHeavy menstrual bleedingBaseline to weekOral GnRH antagonistPresence of fibroidsNon-surgical approachFocused ultrasoundFibroid volumeMyoma volumeArtery embolizationMenstrual bleedingCurrent management strategiesGnRH antagonistEchographic guidanceSurgical interventionFibroidsInfertilityMedical treatmentUterineWomenOptimal dosageSource of controversy
2023
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set
Cooper N, Rivas C, Munro M, Critchley H, Clark T, Matteson K, Papadantonaki R, Yorke S, Tan A, Rodriguez M, Bongers M, Al‐Hendy A, Bahamondes L, Connolly A, Farquhar C, Valbrun T, Hickey M, Taylor H, Toub D, Vannuccini S, Iliodromiti S, Khan K. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG An International Journal Of Obstetrics & Gynaecology 2023, 130: 1337-1345. PMID: 37055716, DOI: 10.1111/1471-0528.17473.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingCore outcomeFinal COSMenstrual bleedingClinical trialsConsensus meetingSystematic reviewSeverity of dysmenorrhoeaNumber of patientsPotential core outcomesInternational Consensus MeetingQuality of lifeDelphi surveyTwo-round Delphi surveyAdverse eventsBlood lossHemoglobin levelsFuture trialsGynecology DepartmentCOMET InitiativePatient satisfactionClinical guidelinesResource settingsOnline international surveyFurther treatment
2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet 2022, 400: 896-907. PMID: 36116480, DOI: 10.1016/s0140-6736(22)01475-1.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingPhase 3 trialSymptomatic uterine fibroidsMenstrual bleedingUterine fibroidsTherapy groupPlacebo groupOral gonadotropin-releasing hormone receptor antagonistResponse rateGonadotropin-releasing hormone receptor antagonistCommon adverse eventsFull analysis setHormone receptor antagonistDose of treatmentMasked treatmentPrimary endpointStudy drugAdverse eventsEligible womenHot flushesChronic treatmentReceptor antagonistGonadal steroidsLinzagolixAnalysis setPost-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]
Taylor H, Donnez J, Bestel E, Humberstone A, Garner E. Post-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]. Obstetrics And Gynecology 2022, 139: 31s-32s. DOI: 10.1097/01.aog.0000826752.16466.97.Peer-Reviewed Original ResearchBone mineral densityUterine fibroidsWeek 64Placebo-controlled phase 3 trialLumbar spine bone mineral densityTreatment of UFsSpine bone mineral densityHeavy menstrual bleedingPhase 3 trialWeeks of dosingHealth-related qualityCompletion of treatmentTreatment of womenEfficacy endpointPost-treatment efficacyTreatment discontinuationUterine bleedingWeek 52Key efficacyWeek 76Menstrual bleedingFibroid volumeMedian timeFollow-upMineral density
2021
O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials
Taylor H, Donnez J, Petraglia F, Danielsson K, Renner S, Bestel E, Gotteland J, Humberstone A, Garner E. O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials. Human Reproduction 2021, 36: deab126.060. DOI: 10.1093/humrep/deab126.060.Peer-Reviewed Original ResearchHeavy menstrual bleedingQuality of lifePhase 3 trialWeeks of treatmentUterine fibroidsPain scoresSecondary endpointsMenstrual bleedingMean agePlacebo-controlled phase 3 trialPotential long-term treatmentOral GnRH antagonistSecondary efficacy assessmentsTrial subjectsTRIAL REGISTRATION NUMBERDifferent treatment regimensLong-term treatmentPARTICIPANTS/MATERIALSROLE OF CHANCEMaintenance of effectsSymptom recurrenceSecondary efficacySymptomatic improvementWeek 24Anemic patients
2017
Current and Emerging Medical Treatments for Uterine Fibroids
Chwalisz K, Taylor H. Current and Emerging Medical Treatments for Uterine Fibroids. Seminars In Reproductive Medicine 2017, 35: 510-522. PMID: 29100239, DOI: 10.1055/s-0037-1606302.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCost of IllnessDrug ApprovalDrugs, InvestigationalEvidence-Based MedicineFemaleGonadotropin-Releasing HormoneHormone AntagonistsHumansLeiomyomaLeiomyomatosisMenorrhagiaQuality of LifeReceptors, ProgesteroneUnited StatesUnited States Food and Drug AdministrationUterine NeoplasmsConceptsUterine fibroidsMedical therapyMedical treatmentOral gonadotropin-releasing hormone antagonistLong-term medical therapyGonadotropin-releasing hormone antagonistCommon uterine neoplasmPressure-related symptomsHeavy menstrual bleedingProgesterone receptor modulatorsRandomized clinical trialsSymptomatic uterine fibroidsUnited States FoodMenstrual bleedingUterine neoplasmsSymptom managementSurgical interventionHormone antagonistClinical trialsReceptor modulatorsMedical optionsEffective treatmentClinical developmentFibroidsDrug Administration
2014
Uterine Fibroids: Clinical Manifestations and Contemporary Management
Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive Sciences 2014, 21: 1067-1092. PMID: 24819877, DOI: 10.1177/1933719114533728.Peer-Reviewed Original ResearchConceptsMedical therapyUterine fibroidsGrowth factorAbnormal uterine bleedingHeavy menstrual bleedingInterventional radiological proceduresEndometrial effectsUterine bleedingMenstrual bleedingMedical managementSurgical managementCommon lesionsCurrent armamentariumFibroid treatmentClinical trialsEffective treatmentFibroidsRadiological proceduresDrug AdministrationFibroid cellsNovel therapeuticsAbnormal regulationTherapyFibroid biologyMolecular changes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply